Form D · Pharmaceuticals
Clarus Therapeutics Holdings, Inc.
Northbrook, IL · CIK 0001817944
Offering snapshot reported Dec 21, 2021 · SEC filing
- Reported sold
- $15M Offering amount: $15M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 7, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 21, 2021 | Initial | $15,000,002 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $900K
- Finders' fees
- $0
- Form D file number
- 021-426026
Private placement of shares of common stock, warrants to purchase shares of common stock at an exercise price of $5.25 and pre-funded warrants at an exercise price of $0.00001
Source: Form D, filed Dec 21, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Kenneth Amory | Director |
| Steven A. Bourne | Executive |
| Elizabeth Cermak | Director |
| Robert E. Dudley | Director, Executive |
| Joseph Hernandez | Director |
| Frank Jaeger | Executive |
| Kimberly Murphy | Director |
| Richard Peterson | Executive |
| Mark A. Prygocki | Director |
| Alex Zisson | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
555 Skokie Boulevard, Suite 340
Northbrook, IL, 60062
Northbrook, IL, 60062